Subset-specific alterations in frequencies and functional signatures of γδ T cells in systemic sclerosis patients

Inflammation Research

Volumn 65, Issue 12, 2016, Pages 985-994

  Henriques, Ana ^a,b   Silva, Cláudia ^a,c   Santiago, Mariana ^a,d   Henriques, Maria João ^a,d   Martinho, António ^b   Trindade, Hélder ^b   da Silva, José António Pereira ^a,d   Silva Santos, Bruno ^e   Paiva, Artur ^b,d  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b IP   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

CD27; Cytotoxicity; Gamma delta T cells; Systemic sclerosis; Th1 type cytokine

Indexed keywords

EOMESODERMIN; GAMMA INTERFERON; GRANZYME A; GRANZYME B; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; TUMOR NECROSIS FACTOR; CD27 ANTIGEN;

ADULT; ARTICLE; BLOOD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE DURATION; FEMALE; FLOW CYTOMETRY; GAMMA DELTA T LYMPHOCYTE; GENE EXPRESSION; HUMAN; LUNG FIBROSIS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC SCLEROSIS; T LYMPHOCYTE SUBPOPULATION; AGED; IMMUNOLOGY;

ADULT; AGED; ANTIGENS, CD27; FEMALE; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTE SUBSETS;

EID: 84984831708     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-016-0982-6     Document Type: Article

References (31)

1. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;117:557–67.
2. Gu YS, Kong J, Cheema GS, Keen CL, Wick G, Gershwin ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum. 2008;38:132–60.
3. Domsic RT, Medsger TA Jr. Disease subsets in clinical practice. In: Varga J, Denton C, Wigley F, editors. Scleroderma: from pathogenesis to comprehensive management. New York: Springer; 2012. p. 45–52.
4. Chung L, Fransen J, van den Hoogen F. Evolving concepts of diagnosis and classification. In: Varga J, Denton C, Wigley F, editors. Scleroderma: from pathogenesis to comprehensive management. New York: Springer; 2012. p. 54–69.
5. Tiev KP, Abriol J, Burland MC, Antonelli D, Klatzmann D, Cabane J, Boyer O. T cell repertoire in patients with stable scleroderma. Clin Exp Immunol. 2005;139:348–54.
6. Fuschiotti P, Larregina AT, Ho J, Feghali-Bostwick C, Medsger TA Jr. Interleukin-13-producing CD8 + T cells mediate dermal fibrosis in patients with systemic sclerosis. Arthritis Rheum. 2013;65:236–46.
7. Stummvoll GH, Aringer M, Grisar J, Steiner CW, Smolen JS, Knobler R, Graninger WB. Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis. 2004;63:569–74.
8. Su D, Shen M, Li X, Sun L. Roles of gammadelta T cells in the pathogenesis of autoimmune diseases. Clin Dev Immunol. 2013;2013:985753.
9. Holcombe RF, Baethge BA, Wolf RE, Betzing KW, Stewart RM. Natural killer cells and γδ T-cells in scleroderma: relationship to disease duration and anti-Scl-70 antibodies. Ann Rheum Dis. 1995;54:69–72.
10. Giacomelli R, Matucci-Cerinic M, Cipriani P, Ghersetich I, Lattanzio R, Pavan A, Pignone A, Cagnoni ML, Lotti T, Tonietti G. Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum. 1998;41:327–34.
11. Born WK, O’Brien RL. γδ T cells develop, respond and survive—with a little help from CD27. Eur J Immunol. 2011;41:26–8.
12. Ribot JC, deBarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, Girardi M, Borst J, Hayday AC, Pennington DJ, Silva-Santos B. CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin-17-producing gammadelta T cell subsets. Nat Immunol. 2009;10:427–36.
13. Ribot JC, Chaves-Ferreira M, d’Orey F, Wencker M, Goncalves-Sousa N, Decalf J, Simas JP, Hayday AC, Silva-Santos B. Cutting edge: adaptive versus innate receptor signals selectively control the pool sizes of murine IFN-gamma or IL-17-producing gammadelta T cells upon infection. J Immunol. 2010;185:6421–5.
14. Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Salerno A. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med. 2003;198:391–7.
15. DeBarros A, Chaves-Ferreira M, d’Orey F, Ribot JC, Silva-Santos B. CD70-CD27 interactions provide survival and proliferative signals that regulate T-cell receptor-driven activation of human gamma-delta peripheral blood lymphocytes. Eur J Immunol. 2011;41:195–201.
16. ARA. Subcommittee for scleroderma criteria of the american rheumatism association diagnostic and therapeutic criteria committee. preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–90.
17. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.
18. Henriques A, Inês L, Pais ML, da Silva JP, Paiva A. Th17 cells in systemic lupus erythematosus share functional features with Th17 cells from normal bone marrow and peripheral tissues. Clin Rheumatol. 2012;31:483–91.
19. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:research0034.1–11.
20. Riccieri V, Parisi G, Spadaro A, Scrivo R, Barone F, Moretti T, Bernardini G, Strom R, Taccari E, Valesini G. Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. J Rheumatol. 2005;32:283–6.
21. Bendersky A, Markovits N, Bank I. Vgamma9 + gammadelta T cells in systemic sclerosis patients are numerically and functionally preserved and induce fibroblast apoptosis. Immunobiology. 2010;215:380–94.
22. Qin G, Mao H, Zheng J, Sia SF, Liu Y, Chan PL, Lam KT, Peiris JS, Lau YL, Tu W. Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses. J Infect Dis. 2009;200:858–65.
23. Zhu P, Martinvalet D, Chowdhury D, Zhang D, Schlesinger A, Lieberman J. The cytotoxic T lymphocyte protease granzyme A cleaves and inactivates poly(adenosine 5′-diphosphate-ribose) polymerase-1. Blood. 2009;114:1205–16.
24. Casciola-Rosen L, Andrade F, Ulanet D, Wong WB, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med. 1999;190:815–26.
25. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol. 2005;6:928–37.
26. Intlekofer AM, Banerjee A, Takemoto N, Gordon SM, Dejong CS, Shin H, Hunter CA, Wherry EJ, Lindsten T, Reiner SL. Anomalous type 17 response to viral infection by CD8 T cells lacking T-bet and eomesodermin. Science. 2008;321:408–11.
27. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, Banica M, DiCioccio CB, Gross DA, Mao CA, Shen H, Cereb N, Yang SY, Lindsten T, Rossant J, Hunter CA, Reiner SL. Control of effector CD8 T cell function by the transcription factor Eomesodermin. Science. 2003;302:1041–3.
28. Banerjee A, Gordon SM, Intlekofer AM, Paley MA, Mooney EC, Lindsten T, Wherry EJ, Reiner SL. Cutting edge: the transcription factor eomesodermin enables CD8 T cells to compete for the memory cell niche. J Immunol. 2010;185:4988–92.
29. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8 T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity. 2010;32:67–78.
30. Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210.
31. Champagne E. γδ T cell receptor ligands and modes of antigen recognition. Arch Immunol Ther Exp (Warsz). 2011;59:117–37 (Review).